CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma
Se Un Jeong, Hee Sang Hwang, Ja-Min Park, Sun Young Yoon, Su-Jin Shin, Heounjeong Go, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho
Cancer Research and Treatment. 2023;55(1):231-244.   Published online 2022 March 2    DOI: https://doi.org/10.4143/crt.2021.1526

Excel Download

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma
Cancer Research and Treatment. 2023;55(1):231-244   Crossref logo
Link1 Link2 Link3

VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma
Annals of Oncology. 2010;21(2):431-432   Crossref logo
Link1 Link2 Link3

Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?
European Urology. 2021;79(6):793-795   Crossref logo
Link1 Link2

Upregulation of Pole2 Promotes Clear Cell Renal Cell Carcinoma Progression via AKT/mTOR Pathway and Predicts a Poor Prognosis
. 2020;   Crossref logo
Link1 Link2

PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review
Kidney Cancer. 2021;5(1):31-46   Crossref logo
Link1

TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
. 2020;   Crossref logo
Link1 Link2

Upregulation of ARNTL2 Predicts Poor Survival for Clear Cell Renal Cell Carcinoma and Explores its Associations with PD-L1 and Immune Infiltration
. 2021;   Crossref logo
Link1 Link2

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
Cancer Chemotherapy and Pharmacology. 2015;75(5):1025-1035   Crossref logo
Link1 Link2 Link3

Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma
Laboratory Investigation. 2022;102(4):352-362   Crossref logo
Link1 Link2 Link3 Link4 Link5

Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)
Annals of Oncology. 2018;29:viii311   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.